Associate Professor Branwen Morgan is a science research and strategy consultant. She has worked for a wide variety of not-for-profit and industry organisations in the UK and Australia including the Garvan Institute and AstraZeneca Australia. Bran currently has a role that is split between the Future Industries Institute at the University of South Australia and the Faculty of Science at the University of Technology Sydney.
As well as being an Industry Associate Research Professor, she is the executive officer and 'co-founder’ of OUTBREAK - an intelligence-driven decision support system taking a One Health approach - integrating data from humans, animals, plants and the environment to address the location-specific and person-specific threat of an antibiotic resistant infection. The OUTBREAK consortium brings together 14 organisations across industry, academia and end users and is funded through the Medical Research Future Fund Frontier Health and Medical Research program.
Member, Australian Institute of Company Directors
Member, Australian Society for Microbiology
Member, Australiasian Genomic Technologies Association
Technological Sciences Cluster Respresentative, Science Technology Australia Board
Djordjevic, SP & Morgan, BS 2019, 'A One Health genomic approach to antimicrobial resistance is essential for generating relevant data for a holistic assessment of the biggest threat to public health', Microbiology Australia, vol. 40, no. 2, pp. 73-76.View/Download from: Publisher's site
© 2019 Microbiology Australia. All rights reserved. Antimicrobial resistance (AMR) threatensmodernmedicine asweknow it.AMR infectionsmay ultimately beuntreatable and routine surgeries will become inherently risky1. By 2050 more people may die of drug-resistant infections (DRIs) every year than of cancer, which equates to more than 10 million annual deaths globally2 and the World Bank has estimated that AMR could cost the global economy 1 trillion every year after 2030.DRIs alsolead to an increase in the length of hospital stays, the use of more toxic or costly antibiotics and an increased likelihood of death3. BRIC nations (Brazil, Russia, India, China) and socio-economically challenged countries and people who already have higher rates of infectious diseases will feel the greatest impact2. Indeed, AMR has been likened to the 2008 global financial crisis on an annual repeat cycle.Thatis because the effects of AMR are not just confined to the human medical sector. The veterinary sector is also reliant on the availability of antimicrobials to treat infectious diseases in companion and food-producing animals.
As per OUTBREAK project website.